Revance Therapeutics Inc (NASDAQ:RVNC)

31.07
Delayed Data
As of Jun 02
 +0.66 / +2.17%
Today’s Change
11.27
Today|||52-Week Range
37.98
+68.31%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Year
Trend

2015

2016

2017

2018
Revenue and IncomeNet Revenues300.0K300.0K262.0K3.7M
 
 
 
 
 
Depreciation And Amortization2.0M1.4M1.5M1.7M
 
 
 
 
 
 
Operating ExpensesGross Income-1.7M------
 
 
General Expenses70.6M78.0M116.3M144.6M
 
 
 
 
 
Research And Development47.5M50.4M80.4M92.5M
 
 
 
 
 
Total Operating Expenses72.6M79.5M117.8M146.4M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-72.3M-79.2M-117.5M-142.6M
 
 
 
 
 
Extraordinary Credit127.0K0.000.000.00
 
 
Extraordinary Charge0.00-9.7M-3.5M-140.0K
 
 
 
 
Interest Expense On Debt1.2M1.1M570.0K44.0K
 
 
 
 
 
Other Expenses-327.0K-535.0K-525.0K-773.0K
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-73.5M-89.3M-120.6M-139.6M
 
 
 
 
 
Income Taxes0.000.000.00-3.0M
 
 
Net Income-73.5M-89.3M-120.6M-142.6M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS24.3M28.1M30.1M36.2M
 
 
 
 
 
Shares To Calculate EPS Diluted24.3M28.1M30.1M36.2M
 
 
 
 
 
 
Earnings Per ShareEPS-$3.02-$3.18-$4.01-$3.94
 
 
 
 
 
EPS Diluted-$3.02-$3.18-$4.01-$3.94